Revenue → Gross profit: DKK9.8BDiabetes care → Revenue: DKK8.3BGLP-1 → Diabetes care: DKK5.9BGross profit → Operating profit: DKK5.8BOperating profit → Net profit: DKK4.4BGross profit → Operating cost: DKK4.0BObesity care → Revenue: DKK2.8BInsulin → Diabetes care: DKK2.2BOperating cost → Sales & distribution: DKK2.2BRevenue → Cost of sales: DKK1.9BOperating cost → R&D: DKK1.5BOperating profit → Tax: DKK1.2BRare disease → Revenue: DKK0.7BOperating profit → Financial items: DKK0.3BOperating cost → Administrative costs: DKK0.2BOther diabetes → Diabetes care: DKK0.1BOperating cost → Other costs: DKK0.0BAdministrative costsDKK0.2B5% Y/YCost of salesDKK1.9B30% Y/YDiabetes careDKK8.3B10% Y/YFinancial itemsDKK0.3B2342% Y/YGLP-1DKK5.9B13% Y/YGross profitDKK9.8B18% Y/YInsulinDKK2.2B4% Y/YNet profitDKK4.4B14% Y/YObesity careDKK2.8B67% Y/YOperating costDKK4.0B12% Y/YOperating profitDKK5.8B21% Y/YOther costs$2.1MOther diabetesDKK0.1B-19% Y/YR&DDKK1.5B20% Y/YRare diseaseDKK0.7B5% Y/YRevenueDKK11.7B19% Y/YSales & distributionDKK2.2B12% Y/YTaxDKK1.2B23% Y/YNovo Nordisk Q1 FY25 Income Statementcreated with SankeyArt.com
Copy and edit diagram